DRG Market Assessment reports

Immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab ± ipilimumab, and nivolumab plus relatlimab) and BRAF/MEK inhibitor combinations (e.g., vemurafenib plus cobimetinib) have greatly…

In the dynamic Parkinson’s disease (PD) market, recent advancements have been matched by notable challenges. Although the introduction of new brands, including Acorda’s Inbrija and AbbVie’s…

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenia and the risk of progression to acute myeloid leukemia (AML). Bristol…

Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus and eczema. Key goals of AD treatment are to protect the skin barrier, reduce inflammation, and alleviate itch…

Clarivate Epidemiology’s coverage of spinal muscular atrophy (SMA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…

Major depressive disorder (MDD) is typically treated with psychotherapy, pharmacotherapy, or a combination of the two. The MDD therapy market is highly genericized; for patients experiencing…

CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio/Verzenios) combined with endocrine therapy are central to the treatment of metastatic hormone receptor-…

Although TNF-alpha inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) refractory to conventional DMARD treatment (the first-line standard of care), the RA drug…

The number of total prevalent cases of SAD in the countries under study will increase by 7% from 21 million to 23 million in 20 years. Of the countries considered in this analysis, the total…

Clarivate Epidemiology’s coverage of social anxiety disorder comprises epidemiological estimates of key patient populations across seven countries worldwide. We report the prevalence of social…

Clarivate Epidemiology’s coverage of community-acquired bacterial pneumonia (CABP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…

Eisai / Biogen’s Leqembi (lecanemab) has launched for the treatment of early AD in the United States and Japan. However, it is facing challenges in Europe, including a negative opinion from the…